Home / Evidence ledger / BPC-157
15 amino acids · synthetic · gastric-derived sequence
Under reviewA 15-amino-acid synthetic peptide with a large preclinical literature and, as of today, no completed controlled human efficacy trial. An FDA advisory panel voted narrowly in its favour in July 2026, against the recommendation of the agency's own scientists.
Free, no obligation
Every inquiry gets a real answer from a person. If what you're asking about isn't supported by evidence, we'll say so.
Schematic structure, not to scale. Beads represent amino acid residues along the backbone.
In theory, BPC-157 is designed to accelerate tissue repair, driving new blood vessel growth into damaged tendon, ligament and gut tissue, and upregulating growth factor receptors at the site of injury. That is the hypothesis, and the preclinical literature behind it is unusually consistent: many independent labs, many injury models, the same direction of effect.
The detail, if you want it
BPC-157 stands for Body Protection Compound 157. It is a synthetic chain of fifteen amino acids derived from a sequence found in human gastric juice. It does not exist in the body in this form. The parent protein does, but BPC-157 itself is a laboratory construct.
The preclinical literature attributes its effects to promotion of new blood vessel growth, largely through VEGFR2 signalling and the nitric oxide pathway, along with upregulation of growth factor receptors in healing tissue. These mechanisms are plausible and reasonably well described in preclinical models. Whether any of it translates to humans at the doses people use is unknown.
That is the question a consultation answers. A licensed physician reviews your situation and tells you what the evidence supports. Including when the honest answer is no.
See consultationsAlso on the ledger